The authors reply
- PMID: 40590647
- DOI: 10.1097/CCM.0000000000006695
The authors reply
Conflict of interest statement
Dr. Tamura’s institution received funding from Taiyo Nippon Sanso Corporation. Drs. Tamura, Homma, and Suzuki disclosed off-label use of hydrogen gas. Dr. Homma received support for article research from companies. Dr. Sano received funding from Doctors Man. Dr. Suzuki received support for article research from Taiyo Nippon Sanso Corporation. Dr. Narumiya has disclosed that he does not have any potential conflicts of interest.
References
-
- Gonze A, Gennart T, Perriens E, et al.: High mortality at 90 days in the control group of target temperature management 32–34°C: Was the 4-hour therapeutic window for hypothermia efficacy applied? Crit Care Med 2025; 53:e1514–e1515
-
- Tamura T, Narumiya H, Homma K, et al.; Efficacy of Inhaled Hydrogen on Neurologic Outcome Following Brain Ischemia During PostCardiac Arrest Care (HYBRID II) Study Group: Combination of hydrogen inhalation and hypothermic temperature control after out-of-hospital cardiac arrest: A post hoc analysis of the efficacy of inhaled hydrogen on neurologic outcome following brain ischemia during postcardiac arrest care II trial. Crit Care Med 2024; 52:1567–1576
-
- Beurskens CJ, Horn J, de Boer AMT, et al.: Cardiac arrest patients have an impaired immune response, which is not influenced by induced hypothermia. Crit Care 2014; 18:R162
-
- Kimura A, Sakurada S, Ohkuni H, et al.: Moderate hypothermia delays proinflammatory cytokine production of human peripheral blood mononuclear cells. Crit Care Med 2002; 30:1499–1502
-
- Perman SM, Ellenberg JH, Grossestreuer AV, et al.: Shorter time to target temperature is associated with poor neurologic outcome in post-arrest patients treated with targeted temperature management. Resuscitation 2015; 88:114–119